Novo Nordisk pushes back on Foundayo comparisons the same day

Novo Nordisk's US operations head, Jamey Millar, pushed back on comparisons between orforglipron, an experimental pill from Eli Lilly known by the brand name Foundayo, and Novo Nordisk's Wegovy pill. Millar said reports claiming orforglipron is more effective than the Wegovy pill for weight management were "inaccurate and misleading" ^[1].

The statement frames the two oral drugs as clinically distinct products rather than direct substitutes, according to the summary of Millar's remarks ^[1]. Wegovy is a brand name for semaglutide, a GLP-1 medicine that Novo Nordisk also sells as Ozempic for diabetes and as Rybelsus in pill form. Orforglipron, Eli Lilly's oral GLP-1 candidate marketed under the name Foundayo, works on the same hormone pathway but is a different molecule.

The underlying source describing this exchange was not accessible in full, so it is not yet known exactly which reports or data points Millar was responding to, what specific numbers or study results were cited in those reports, or whether Eli Lilly has responded to his characterization. It is also not known from available material whether Millar cited head-to-head trial data, sales figures, or another basis for his statement.

Why it matters for patients

For people choosing between weight-loss pills, public disputes between drugmakers about whose product works better can be confusing. When a company executive calls comparative claims "inaccurate and misleading" without the underlying data being available to reporters or the public, patients are left without a clear way to judge the competing claims themselves ^[1].

This matters because Wegovy and orforglipron are both oral GLP-1 medicines being positioned for weight management, but they are not the same drug and may not produce identical results, side effects, or costs. Patients and their doctors typically rely on published clinical trial results, not corporate statements, to compare how well different medicines work and what risks they carry. Corporate pushback on comparison claims, on its own, does not provide the kind of data needed to make an informed choice.

Patients currently using or considering either Wegovy or a future orforglipron pill should know that the companies making these drugs have a financial interest in how their products are perceived relative to competitors. A statement calling a comparison "misleading" is not the same as new clinical evidence, and none of the specific evidence behind Millar's claim was available in the source reviewed for this article ^[1].

What happens next

It is not yet known from the available source when or whether Novo Nordisk will release additional data or statements to support Millar's position, or whether Eli Lilly will issue a public response. Orforglipron's regulatory status and availability timeline in the United States are also not detailed in the source reviewed here. Readers should watch for statements from both companies, along with any peer-reviewed trial results, as a more reliable way to compare the two drugs than executive commentary alone.

Because the full text of the source describing this dispute could not be reviewed, this article is limited to what was stated in the development summary: that Millar, described as Novo Nordisk's US operations head, called comparisons favoring orforglipron over the Wegovy pill "inaccurate and misleading" ^[1]. Further reporting will be needed to confirm the specifics of the claims being disputed and any evidence either company presents to support its position.